SCHEMBL4789540

SCHEMBL4789540

CCOC(=O)c1cc2c(ccc(=O)n2-c2ccccc2)n1Cc1ccccc1C#N

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 10/20 0.49
KDM4E B2RXH2 8/20 0.49
TDP1 Q9NUW8 5/20 0.49
TSHR P16473 3/20 0.49
RECQL P46063 1/20 0.49
HSD17B10 Q99714 1/20 0.49
ALDH1A1 P00352 6/20 0.48
MAPK1 P28482 2/20 0.48
L3MBTL1 Q9Y468 1/20 0.48
NPSR1 Q6W5P4 3/20 0.42
RXFP1 Q9HBX9 1/20 0.41
POLB P06746 1/20 0.41
ATM Q13315 1/20 0.41
GAA P10253 2/20 0.40
MEN1 O00255 2/20 0.40
KMT2A Q03164 2/20 0.40
FEN1 P39748 1/20 0.40
LMNA P02545 1/20 0.40
SMN1; SMN2 Q16637 1/20 0.40
NOX4 Q9NPH5 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4715382 0.87 FEN1 (0.47) MAPTTDP1TSHRRECQLALDH1A1
SCHEMBL4760166 0.85 NOX4 (0.43) TSHRALDH1A1NPSR1RXFP1FEN1
SCHEMBL4716102 0.84 MAPT (0.57) MAPTKDM4ETDP1TSHRRECQL
SCHEMBL4789434 0.79 ALDH1A1 (0.53) MAPTKDM4ETDP1TSHRRECQL
SCHEMBL4713175 0.78 MAPT (0.46) MAPTKDM4ETDP1TSHRRECQL
SCHEMBL4712174 0.78 MAPT (0.51) MAPTKDM4ETDP1TSHRRECQL
Phenylboronic Acid SCHEMBL6530013 0.78 MAPT (0.51) MAPTKDM4ETDP1TSHRRECQL
SCHEMBL4715422 0.77 MAPT (0.48) MAPTKDM4ETDP1TSHRRECQL
SCHEMBL4711774 0.76 MAPT (0.51) MAPTKDM4ETDP1TSHRRECQL
SCHEMBL4717230 0.75 MAPT (0.47) MAPTKDM4ETDP1TSHRRECQL

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7456286-B2 Bicyclic heteroaromatic compounds as kinase inhibitors UCB PHARMA, S.A. (BE) 2008-11-25 US disclosed
EP-1549648-B1 BICYCLIC HETEROAROMATIC COMPOUNDS AS KINASE INHIBITORS UCB PHARMA SA (BE) 2008-11-12 EP disclosed
US-20060122212-A1 Bicyclic heteroaromatic compounds as kinase inhibitors CELLTECH R&D LIMITED (GB) 2006-06-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060122212-A1 Bicyclic heteroaromatic compounds as kinase inhibitors MAP2K2, MAP2K7, MAP2K3 MAPT 1831/4885KDM4E 2030/4885TDP1 983/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.